Verified Supplement Data Primary-sourced

Cranberry for UTI Prevention: What the Evidence Really Shows

By Erin Rose · Updated · Methodology

Educational summary — not medical advice. Cranberry is an adjunct for reducing the risk of recurrent UTIs, not a treatment for an active infection — if you have UTI symptoms, see a clinician. This statement has not been evaluated by the FDA. This product is not intended to diagnose, treat, cure, or prevent any disease.

The honest answer

Cranberry modestly reduces the risk of recurrent UTIs — the 2023 Cochrane review found RR 0.74 (95% CI 0.55–0.99, moderate certainty) in women and RR 0.46 in children (Williams 2023). But the evidence is mixed: a 2016 JAMA nursing-home trial was null (Juthani-Mehta 2016), and the most direct dose-controlled trial was null on its primary endpoint (Babar 2021). It's prevention, not treatment, and it works by bacterial anti-adhesion — not by acidifying urine. Two cautions matter: warfarin and oxalate/kidney stones.

The mechanism is anti-adhesion, not acidification

Cranberry's A-type proanthocyanidins (PACs) reduce recurrent-UTI risk by bacterial anti-adhesion — they interfere with the P-fimbriae that uropathogenic E. coli use to grip the bladder wall, so bacteria are more easily flushed out (Howell 2010). The old "cranberry acidifies your urine and kills bacteria" story is largely outdated; the modern, evidence-based mechanism is anti-adhesion, and it only holds at a real A-type PAC dose (~36 mg/day), which most products don't disclose (the label trap). This matters clinically: because it's anti-adhesion, cranberry is a preventive that lowers the odds of the next infection, not something that clears one already established.

What the trials show — and where they stop

Read the strong review alongside the honest nulls. These are different studies asking overlapping questions:

StudyPopulationFindingThe honest limit
Williams 2023 (Cochrane)
PMID 37068952		 Systematic review; women, children, and at-risk groups Recurrent UTI in women RR 0.74 (95% CI 0.55–0.99); children RR 0.46; post-intervention RR 0.47 Benefit clearest in women with recurrent UTIs and in children — not in every group; certainty moderate
Juthani-Mehta 2016 (JAMA)
PMID 27787564		 RCT, older women in nursing homes Cranberry capsules: no reduction in bacteriuria plus pyuria A clear null in an elderly institutional population — the effect doesn't generalize everywhere
Babar 2021 (PACCANN)
PMID 33757474		 RCT, women with recurrent UTIs (dose-controlled) Null on its primary endpoint; only exploratory post-hoc signals The most direct dose-comparison trial missed its primary outcome — treat post-hoc findings as hypothesis-generating

Read together: the pooled review supports a modest reduction in recurrent-UTI risk for the right people (women and children who get frequent UTIs), while individual trials in other populations — and even the most rigorous dose-controlled trial — came up null. A 2024 meta-analysis helps reconcile this with a dose signal: trials using ≥36 mg PAC/day cut risk (RR 0.82) while lower doses didn't (Xiong 2024) — so under-dosing (and undisclosed PAC) plausibly explains some nulls.

On the 2012 → 2023 "reversal" This wasn't cranberry suddenly starting to work. The 2012 Cochrane review reached an equivocal verdict and didn't support recommending it (Jepson 2012). By 2023, more and better trials had been added; the pooled point estimate for recurrent UTIs in women stayed near RR 0.74, but the confidence interval tightened enough to reach significance and moderate certainty (Williams 2023). It's a certainty upgrade, not a new effect.

Who it's most reasonable for

  • Women and children with recurrent UTIs — where the risk reduction was clearest (Williams 2023).
  • As an adjunct for prevention — alongside hydration, hygiene, and any strategy your clinician recommends; not a replacement for medical care, and not an antibiotic.
  • People who'll actually dose the PAC — aim for a disclosed ~36 mg A-type PAC/day; most products can't confirm this, so favor one that discloses PAC (the comparison).

Skip or get medical advice first if you: have symptoms of an active UTI (see a clinician — this is prevention, not treatment); take warfarin (INR monitoring); or form calcium-oxalate kidney stones (concentrated tablets raise urinary oxalate).

Frequently asked questions

Does cranberry prevent UTIs?

Modestly, for recurrent UTIs — RR 0.74 in women, RR 0.46 in children (Williams 2023, moderate certainty). Real but small, and it's prevention by bacterial anti-adhesion, not treatment of an active infection.

Why did the verdict change from 2012 to 2023?

A certainty upgrade, not a new effect. The 2012 review (Jepson) was equivocal; by 2023 more trials tightened the confidence interval around a similar ~0.74 point estimate, reaching significance and moderate certainty (Williams 2023).

Can I take it to treat a UTI I already have?

No. It's studied for reducing recurrent-UTI risk over time, not clearing an active infection. UTI symptoms (burning, urgency, fever) need a clinician — a real infection usually needs antibiotics.

Is it safe with warfarin or if I get kidney stones?

Warfarin: mixed evidence (case reports and a +30% AUC study vs a null RCT) — caution with INR monitoring. Kidney stones: concentrated tablets raised urinary oxalate (Terris 2001), so stone-formers should be cautious.

Related

Sources

  1. Williams G, et al. "Cranberries for preventing urinary tract infections." Cochrane Database Syst Rev. 2023. PMID: 37068952
  2. Jepson RG, et al. "Cranberries for preventing urinary tract infections." Cochrane Database Syst Rev. 2012. PMID: 23076891 (prior equivocal verdict).
  3. Juthani-Mehta M, et al. "Effect of cranberry capsules on bacteriuria plus pyuria among older women in nursing homes: a randomized clinical trial." JAMA. 2016. PMID: 27787564
  4. Babar A, et al. "High dose versus low dose standardized cranberry proanthocyanidin extract for the prevention of recurrent urinary tract infection (PACCANN): a randomized controlled trial." BMC Urol. 2021. PMID: 33757474
  5. Xiong Z, et al. "Cranberry supplementation for the prevention of urinary tract infections: a meta-analysis." Front Nutr. 2024. PMID: 39668896
  6. Howell AB, et al. "Dosage effect on uropathogenic Escherichia coli anti-adhesion activity in urine following consumption of cranberry powder." BMC Infect Dis. 2010. PMID: 20398248
  7. Haber SL, et al. "Cranberry and warfarin interaction: a case report and review of the literature." Consult Pharm. 2012. PMID: 22231999
  8. Rindone JP, et al. "Warfarin-cranberry juice interaction resulting in profound hypoprothrombinemia and bleeding." Am J Ther. 2006. PMID: 16772772
  9. Mohammed Abdul MI, et al. "Pharmacodynamic interaction of warfarin with cranberry but not with garlic in healthy subjects." Br J Pharmacol. 2008. PMID: 18516070
  10. Ansell J, et al. "The absence of an interaction between warfarin and cranberry juice: a randomized, double-blind trial." J Clin Pharmacol. 2009. PMID: 19553405
  11. Terris MK, et al. "Dietary supplementation with cranberry concentrate tablets may increase the risk of nephrolithiasis." Urology. 2001. PMID: 11164137
  12. McHarg T, et al. "Influence of cranberry juice on the urinary risk factors for calcium oxalate kidney stone formation." BJU Int. 2003. PMID: 14616463